In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase

Journal of Chemotherapy

Volumn 28, Issue 3, 2016, Pages 159-163

  Wei, Wenjuan ^a   Yang, Haifei ^a   Liu, Yanyan ^a,b   Ye, Ying ^a,b   Li, Jiabin ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Anhui Center for Surveillance of Bacterial Resistance   (China)

Author keywords

Acinetobacter; Antimicrobial resistance; Combination therapy; Susceptibility; Synergy

Indexed keywords

CARBAPENEMASE; COLISTIN; FOSFOMYCIN; IMIPENEM; LEVOFLOXACIN; RIFAMPICIN; SULBACTAM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA-LACTAMASE OXA-23;

ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OXA 23 GENE; POLYMERASE CHAIN REACTION; ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; IN VITRO STUDY; MICROBIAL SENSITIVITY TEST;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FOSFOMYCIN; HUMANS; IMIPENEM; IN VITRO TECHNIQUES; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; RIFAMPIN; SULBACTAM;

EID: 84978763053     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1973947815Y.0000000030     Document Type: Article

References (27)

1. E.G.Playford, J.C.Craig, J.R.Iredell. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and consequences. J Hosp Infect. 2007;65(3):204–11.
2. N.Karah, A.Sundsfjord, K.Towner, Ø.Samuelsen. Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. Drug Resist Updat. 2012;15(4):237–47.
3. X.Dong, F.Chen, Y.Zhang, H.Liu, Y.Liu, L.Ma. In vitro activities of rifampin, COL, sulbactam and tigecycline tested alone and in combination against extensively drug-resistant Acinetobacter baumannii. J Antibiot. 2014;67(9):677–80.
4. T.D.Gootz, A.Marra. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect Ther. 2008;6(3):309–25.
5. J.Li, R.L.Nation, J.D.Turnidge, R.W.Milne, K.Coulthard, C.R.Rayner, Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.
6. C.Urban, N.Mariano, J.J.Rahal. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother. 2010;54(6):2732–4.
7. P.Pongpech, S.Amornnopparattanakul, S.Panapakdee, S.Fungwithaya, P.Nannha, C.Dhiraputra. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii. J Med Assoc Thai. 2010;93(2):161–71.
8. G.Dinc, H.Demiraslan, F.Elmali, S.S.Ahmed, G.Metan, E.Alp, Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis. Chemotherapy. 2013;59(5):325–9.
9. S.M.Garonzik, J.Li, V.Thamlikitkul, D.L.Paterson, S.Shoham, J.Jacob, Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94.
10. F.C.Odds. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52(1):1.
11. R.Sirijatuphat, V.Thamlikitkul. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(9):5598–601.
12. CLSI, Performance standards for antimicrobial susceptibility testing; Twenty-Fouth informational supplement, M100-S24. Wayne, Pennsylvania, USA: Clinical and Laboratory Standards Institute; 2014.
13. E.Evren, O.K.Azap, Ş.Çolakoğlu, H.Arslan. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA-48 positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis. 2013;76(3):335–8.
14. K.Lee, D.Yong, S.H.Jeong, Y.Chong. Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens. Yonsei Med J. 2011;52(6):879–91.
15. E.Durante-Mangoni, G.Signoriello, R.Andini, A.Mattei, M.De Cristoforo, P.Murino, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57(3):349–58.
16. A.Batirel, I.I.Balkan, O.Karabay, C.Agalar, S.Akalin, O.Alici. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis. 2014;33(8):1311–22.
17. I.Karaoglan, Y.Zer, V.K.Bosnak, A.O.Mete, M.Namiduru. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. J Int Med Res. 2013;41(6):1830–7.
18. H.J.Lee, P.J.Bergen, J.B.Bulitta, B.Tsuji, A.Forrest, R.L.Nation, Synergistic activity of colistin and rifampicin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57(8):3738–45.
19. M.E.Pachón-Ibáñez, F.Docobo-Pérez, R.López-Rojas, J.Domínguez-Herrera, M.E.Jiménez-Mejias, A.García-Curiel, Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54(3):1165–72.
20. M.Giannouli, A.Di Popolo, E.Durante-Mangoni, M.Bernardo, S.Cuccurullo, G.Amato, Molecular epidemiology and mechanisms of rifampicin resistance in Acinetobacter baumannii isolates from Italy. Int J Antimicrob Agents. 2012;39(1):58–63.
21. A.P.Magiorakos, A.Srinivasan, R.B.Carey, Y.Carmeli, M.E.Falagas, C.G.Giske, Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
22. W.Santimaleeworagun, P.Wongpoowarak, P.Chayakul, S.Pattharachayakul, P.Tansakul, K.W.Garey. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health. 2011;42(4):890–900.
23. A.Safarika, I.Galani, A.Pistiki, E.J.Giamarellos-Bourboulis. Time-kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin. Eur J Clin Microbiol Infect Dis. 2014;34(2):317–23.
24. M.Kempf, L.Djouhri-Bouktab, J.M.Brunel, D.Raoult, J.M.Rolain. Synergistic activity of sulbactam combined with colistin-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012;39(2):180–1.
25. A.S.Michalopoulos, I.G.Livaditis, V.Gougoutas. The revival of fosfomycin. Int J Infect Dis. 2011;15(11):e732–9.
26. M.E.Falagas, K.P.Giannopoulou, G.N.Kokolakis, P.I.Rafailidis. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis. 2008;46(7):1069–77.
27. T.Mikuniya, Y.Kato, R.Kariyama, K.Monden, M.Hikida, H.Kumon. Synergistic effect of fosfomycin and fluoroquinolones against Pseudomonas aeruginosa growing in a biofilm. Acta Med Okayama. 2005;59(5):209–16.